Methodological issues in therapeutic trials of COPD
Open Access
- 23 January 2008
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 31 (5) , 927-933
- https://doi.org/10.1183/09031936.00098307
Abstract
The recent Towards a Revolution in COPD Health (TORCH) randomised trial replicated the findings of previous trials in chronic obstructive pulmonary disease (COPD) on the apparent effectiveness of inhaled corticosteroids (ICS) in reducing exacerbation rates, but not so for mortality.In the present article, the authors review methodological issues in the TORCH and previous trials, such as patients already receiving ICS before randomisation and the absence of follow-up after study drug discontinuation, using data from two trials.First, among previous ICS users in the Canadian Optimal Therapy of COPD Trial, the hazard ratio of the first exacerbation with ICS relative to bronchodilators was 0.71 (95% confidence interval (CI) 0.53–0.96), while among those not using ICS prior to randomisation, it was 1.11 (95% CI 0.69–1.79). Secondly, the rate ratio of exacerbations with ICS was 0.78 (95% CI 0.61–0.99) prior to drug discontinuation during follow-up and 1.23 (95% CI 0.78–1.95) thereafter. Finally, a 2×2 factorial analysis of the TORCH data found a rate ratio of mortality for the salmeterol component to be 0.83 (95% CI 0.74–0.95), while for the fluticasone component it was 1.00 (95% CI 0.89–1.13).In conclusion, after proper consideration of the various methodological shortcomings in the design and analysis of randomised trials, the effectiveness of inhaled corticosteroids in treating chronic obstructive pulmonary disease remains doubtful, while the benefit observed with combination therapy may be due exclusively to the beneficial effects of the long-acting bronchodilator alone.Keywords
This publication has 25 references indexed in Scilit:
- Prevention of Death in COPDNew England Journal of Medicine, 2007
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysisThorax, 2003
- Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax, 2003
- Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up studyThorax, 2003
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003
- The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trialsThe American Journal of Medicine, 2002
- Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ, 2000
- Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 1999
- Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug ProjectNew England Journal of Medicine, 1980